Articles by Anna Rose Welch

  1. Will Pay-For-Performance Really Suit The Cancer Drug Space? 6/9/2015

    If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.

  2. FDA News Roundup: Valeant, Pfizer, Boehringer Ingelheim, And More 5/29/2015

    What FDA decisions have you missed recently?

  3. Pharma's Orphan Drug Binge: Redefining Corporate Social Responsibility? 5/26/2015

    A few months ago, Senator Elizabeth Warren launched a proposal for a “swear jar” bill that would require law-breaking Big Pharma companies to contribute 1 percent of the profits from each of their blockbuster drugs to NIH research. While this proposal was highly contested by members of the industry, I questioned if there couldn’t be a benefit to this bill apart from punishing law breakers and bolstering drug R&D. Would seeing pharma push more of its profits into research boost the industry’s image?   

  4. FDA News Roundup: Baxter, Celgene, Agios, And More 5/22/2015

    What FDA decisions have you missed recently?

  5. FDA News Roundup: Vertex, Merck KGaA , Bayer, And More 5/15/2015

    What recent FDA decisions have you missed lately?

  6. Keeping Tabs On Gene Therapy? Big Pharma Is Closing In 5/12/2015

    Some good news for Big Pharma in recent weeks was GSK’s filing with the European Medicines Agency for approval of its gene therapy for ADA Severe Combined Immune Deficiency (ADA-SCID), also known as “bubble boy disease.”

  7. FDA News Roundup: Biogen Idec, GSK, Roche, And More 5/8/2015

    What regulatory decisions have you missed lately?

  8. Are We Seeing Innovation In The “Me Too” Hep C Space? 5/5/2015

    The whirlwind hepatitis C therapeutic market seems to have accelerated in the past few weeks. When I think about industry competition, even the high-profile non-small cell lung cancer (NSCLC) immunotherapy race and the sprint to approve the promising PCSK9 inhibitors for cholesterol pale in comparison to hepatitis C. Perhaps this interest was born out of the drama of the AbbVie/Gilead/Express Scripts pricing hoopla, but it certainly seems this market has grabbed the industry’s attention and won’t let it go.

  9. FDA News Roundup: Kythera Bio, Boehringer Ingelheim, GW Pharma, And More 5/1/2015

    What recent FDA decisions did you miss?

  10. Measuring Pharma Productivity: Should Biopharma Kick Eroom's Law To The Curb? 4/24/2015

    I’m sure you’ve heard that, in terms of new drug approvals, pharma had a productive 2014. There were 51 new treatments approved by the FDA’s Center for Drug Evaluation and Research (CDER) and the FDA’s Center for Biologics Evaluation and Research. According to PhRMA, member companies have invested more than $600 billion on drug R&D since 2000. Last year alone, biopharmaceutical R&D spending hit $51.2 billion.